Mark D. Girgis, MD

Mark Girgis, MD

Assistant Professor in Residence, Department of Surgery, Surgical Oncology

Languages

English

Specialty

Surgery

Institutional Affiliation

Ronald Reagan UCLA Medical Center
UCLA Medical Center, Santa Monica

Education

Fellowship

Surgical Oncology, UPMC Presbyterian, 2014 - 2016

Internship

General Surgery, UCLA School of Medicine, 2007 - 2008

Degree

MD, Loyola University Health System, 2007

Residency

General Surgery, UCLA School of Medicine, 2008 - 2014

Board Certification

Surgery, American Board of Surgery, 2014

Contact Information

Clinical Interests

Adenocarcinoma, Bile Duct, Bile Duct Excision for Benign and Malignant Disease, Bone and Soft Tissue Cancers (Sarcomas), Carcinoid Tumor, Carcinomatosis, Cholecystectomy, Colon Cancer, Gallbladder, Gallstone, Gastrectomy, Gastric Cancer, Gastric Polyps, Gastrointestinal Malignancies, Gastrointestinal Stromal Tumor (GIST), General Surgical Oncology, Hepatobiliary Surgery, Hyperthermic Intraperitoneal Chemotherapy (HIPEC), Liver, Minimally Invasive Surgery, Neuroendocrine Tumors, Pancreas, Pancreatic Cancer, Pancreatic Cysts, Pancreatic Disease, Pancreatic Tumor (Benign), Periampullary Mass, Peritoneal Carcinomatosis, Peritoneal Mesothelioma, Pseudomyxoma Peritonei, Retroperitoneal Sarcoma, Robotic Surgery, Sarcoma, Small Bowel Tumors, Soft Tissue Tumors, Splenectomy (Open and Lap), Stomach Cancer, Stomach Tumor (Benign), Whipple and Pancreatectomy

Scientific Interests

Dr. Mark Girgis' research focuses on developing novel peptides targeting pancreas cancer for radioligand therapy. He is part of a multidisciplinary group that collaborates on a variety of projects centered on developing new therapies for cancer patients.

Highlighted Publications

Ankeny JS, Court CM, Hou S, Li Q, Song M, Wu D, Chen JF, Lee T, Lin M, Sho S, Rochefort MM, Girgis MD, Yao J, Wainberg ZA, Muthusamy VR, Watson RR, Donahue TR, Hines OJ, Reber HA, Graeber TG, Tseng HR, Tomlinson JS. Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. Br J Cancer. 2016 Jun 14;114(12):1367-75. doi: 10.1038/bjc.2016.121.

Rochefort MM, Girgis MD, Knowles SM, Ankeny JS, Salazar F, Wu AM, Tomlinson JS. A mutated anti-CA19-9 scFv-Fc for positron emission tomography of human pancreatic cancer xenografts. Mol Imaging Biol. 2014 Oct;16(5):721-9. doi: 10.1007/s11307-014-0733-4.

Rochefort MM, Girgis MD, Ankeny JS, Tomlinson JS. Metabolic exploitation of the sialic acid biosynthetic pathway to generate site-specifically labeled antibodies. Glycobiology. 2014 Jan;24(1):62-9. doi: 10.1093/glycob/cwt090. Epub 2013 Oct 22.

In the News

View more articles